Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Blueprint Medicines Corporation (Nasdaq: BPMC) announced that as of February 1, 2023, its Compensation Committee has granted non-qualified stock options for 36,260 shares and restricted stock units (RSUs) for 18,119 shares to 24 new employees under the 2020 Inducement Plan. The options have an exercise price of $46.05, reflecting the stock's closing price on the grant date. Options vest 25% after one year, with additional monthly vesting thereafter, while RSUs follow a similar vesting schedule. The grants are in compliance with Nasdaq Listing Rules.

Positive

• Granting stock options and RSUs may enhance employee retention and motivation.
• Stock options reflect the company's share price, aligning employee interests with shareholder value.

Negative

• None.

Argus Session date unavailable

-3.88% session move Open Argus

Details

News Market Reaction – BPMC

The recorded move for BPMC in the trading session of this news was -3.88%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Feb. 7, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective February 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 36,260 shares of its common stock and an aggregate of 18,119 restricted stock units (RSUs) to 24 new employees under Blueprint Medicines' 2020 Inducement Plan.

The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Blueprint Medicines, as an inducement material to such individual's entering into employment with Blueprint Medicines, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of $46.05 per share, which is equal to the closing price of Blueprint Medicines' common stock on February 1, 2023. Each option will vest as to 25% of the shares underlying such option on the first anniversary of the grant date and as to an additional 1/48th of the shares underlying the option monthly thereafter, in each case, subject to each such employee's continued employment on each vesting date. Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each such employee's continued employment on each vesting date. The options and RSUs are subject to the terms and conditions of Blueprint Medicines' 2020 Inducement Plan, and the terms and conditions of the stock option and RSU agreement covering the grant.

About Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate our scientific innovation into a broad pipeline of important approved and investigational precision therapies aimed at addressing difficult-to-treat cancers and blood disorders. Today, we are delivering our approved medicines to patients in the United States, Europe, and in other geographies ourselves or through our partners.  In addition, we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer, and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301741007.html

SOURCE Blueprint Medicines Corporation

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Blueprint Medicines announce on February 7, 2023?

Blueprint Medicines announced the grant of stock options and restricted stock units to new employees under its 2020 Inducement Plan.

How many shares were granted as stock options by Blueprint Medicines?

Blueprint Medicines granted a total of 36,260 shares as stock options.

What is the exercise price for the stock options granted by BPMC?

The exercise price for the stock options is $46.05 per share.

What is the vesting schedule for the RSUs granted by Blueprint Medicines?

The RSUs will vest 25% on the first anniversary of the grant date, with an additional 25% vesting annually thereafter.

What is the significance of the 2020 Inducement Plan for Blueprint Medicines?

The 2020 Inducement Plan is used to grant equity awards to new employees as an inducement for their employment.